EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis

Katie J McMenamin iD, Thomas R Riley iD, Kristin Wipfler iD, Kaleb Michaud, Austin Wheeler iD, Bryant R England iD, Brian Sauer iD, Katherine D Wysham iD, Rui Xiao, Michael March, Grant W Cannon iD, Sylvanus Toikumo und 4 weitere

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25588 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Katie J McMenamin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Boston Medical Center, Boston, Massachusetts. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Polymorphism, Single Nucleotide. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, CSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Several single‐nucleotide polymorphisms (SNPs) have been associated with chronic pain syndromes. Our objective was to determine whether genetic variants are associated with pain and disease activity in rheumatoid arthritis (RA).

Methods

Participants were included from two independent RA cohorts: FORWARD (National Databank for Rheumatic Diseases, training data set) and the Veterans Affairs Rheumatoid Arthritis Registry (VARA; validation data set). Multivariable linear regression was used to estimate the relationship between cross‐sectional pain scores and 36 fibromyalgia (FM)–associated SNPs in FORWARD. SNP alleles were summed and weighted by these regression coefficients to generate a genetic risk score (GRS) for pain for each participant in both cohorts. Linear regressions and generalized estimating equations were used to determine the relationship between this GRS, an existing pain intensity GRS, and pain and self‐reported disease activity.

Results

The sample comprised 756 participants from FORWARD (mean age 56.8 years, 89.4% female) and 2,176 participants from VARA (mean age 64.3 years, 11.0% female) who had pain and genotyping data. Participants in the validation data set (VARA) with FM GRS in the highest quartile had more baseline pain than those in the lowest quartile (+0.55 [95% confidence interval 0.16–0.93], P = 0.006). This was also true for the existing pain intensity GRS. VARA participants in the highest quartile of both GRS had more pain throughout follow‐up and higher disease activity scores.

Conclusion

GRS based on pain‐related SNPs were associated with RA pain and disease activity, suggesting that the genetic risk of pain may have clinical impacts in RA, such as the likelihood of achieving remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPolymorphism, Single NucleotideHumansFemaleMaleMiddle AgedGenetic Predisposition to DiseaseAgedPain MeasurementRisk FactorsCross-Sectional StudiesRisk AssessmentRegistriesFibromyalgiaReproducibility of ResultsSeverity of Illness IndexGenetic Risk Score

Autor:innen und Institutionen

  • Boston Medical Center, Boston, Massachusetts.
  • University of Pennsylvania and Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia.
  • FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas.
  • FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, and VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
  • VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
  • Salt Lake City VA Medical Center and University of Utah, Salt Lake City.

ORCID-Profile: Katie J McMenamin, Thomas R Riley, Kristin Wipfler, Austin Wheeler, Bryant R England, Brian Sauer, Katherine D Wysham, Grant W Cannon, Ted R Mikuls

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • CSRD VA
  • RRD VA
  • Horizon Therapeutics
  • U.S. Department of Defense
  • NIAMS NIH HHS
  • Clinical Science Research and Development

Zitieren

APA

McMenamin, K. J., Riley, T. R., Wipfler, K., Michaud, K., Wheeler, A., England, B. R., Sauer, B., Wysham, K. D., Xiao, R., March, M., Cannon, G. W., Toikumo, S., Kranzler, H. R., Kember, R. L., Mikuls, T. R., & Baker, J. F. (2025). Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis. Arthritis Care & Research. https://doi.org/10.1002/acr.25588

Vancouver

McMenamin KJ, Riley TR, Wipfler K, Michaud K, Wheeler A, England BR, et al. Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis. Arthritis Care & Research. 2025. doi:10.1002/acr.25588

BibTeX
@article{McMenamin2025,
  author = {McMenamin, Katie J and Riley, Thomas R and Wipfler, Kristin and Michaud, Kaleb and Wheeler, Austin and England, Bryant R and Sauer, Brian and Wysham, Katherine D and Xiao, Rui and March, Michael and Cannon, Grant W and Toikumo, Sylvanus and Kranzler, Henry R and Kember, Rachel L and Mikuls, Ted R and Baker, Joshua F},
  title = {Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25588}
}
Kostenlos starten →